Patient Selection for Focal Therapy for Prostate Cancer

2014 ◽  
pp. 29-37
Author(s):  
Alexandre Ingels ◽  
Willemien Van den Bos ◽  
Jean J. M. C. H. de la Rosette
Keyword(s):  
Prostate Cancer ◽  
Patient Selection ◽  
Focal Therapy ◽  
Selection For

1039 PATIENT SELECTION FOR HEMIABLATIVE FOCAL THERAPY OF PROSTATE CANCER BASED ON EXTENDED 14- OR 26-CORE BIOPSY

2011 ◽  
Vol 10 (2) ◽  
pp. 321-322 ◽  
Author(s):  
N. Numao ◽  
S. Kawakami ◽  
M. Sakura ◽  
Y. Komai ◽  
M. Yokoyama ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Patient Selection ◽  
Core Biopsy ◽  
Focal Therapy ◽  
Selection For

MP70-01 UTILITY OF MULTIPARAMETRIC MRI ON PATIENT SELECTION FOR FOCAL THERAPY IN INTERMEDIATE RISK PROSTATE CANCER

2017 ◽  
Vol 197 (4S) ◽  
Author(s):  
Brian Calio ◽  
Abhinav Sidana ◽  
Dordaneh Sugano ◽  
Sonia Gaur ◽  
Amit Jain ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Patient Selection ◽  
Focal Therapy ◽  
Multiparametric Mri ◽  
Intermediate Risk ◽  
Risk Prostate Cancer ◽  
Selection For

scholarly journals Patient selection for hemiablative focal therapy of prostate cancer

Cancer ◽  
2009 ◽  
Vol 115 (10) ◽  
pp. 2104-2110 ◽  
Author(s):  
Thomas J. Polascik ◽  
Janice M. Mayes ◽  
Florian R. Schroeck ◽  
Leon Sun ◽  
John F. Madden ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Patient Selection ◽  
Focal Therapy ◽  
Selection For

scholarly journals A review of optimal prostate biopsy: indications and techniques

2019 ◽  
Vol 11 ◽  
pp. 175628721987007 ◽  
Author(s):  
Justin Streicher ◽  
Brian Lee Meyerson ◽  
Vidhya Karivedu ◽  
Abhinav Sidana
Keyword(s):  
Prostate Cancer ◽  
Patient Selection ◽  
Prostate Biopsy ◽  
Specific Antigen ◽  
Transrectal Ultrasound ◽  
Diagnostic Technique ◽  
Fusion Biopsy ◽  
Advantages And Disadvantages ◽  
Software Platforms ◽  
Selection For

Prostate biopsy is the gold standard diagnostic technique for the detection of prostate cancer. Patient selection for prostate biopsy is complex and is influenced by emerging use of prebiopsy imaging. The introduction of the magnetic resonance imaging (MRI)–transrectal ultrasound (TRUS) fusion prostate biopsy has clear advantages over the historical standard of care. There are several biopsy techniques currently utilized with unique advantages and disadvantages. We review and summarize the current body of literature pertaining to when and how a prostate biopsy should be performed. We discuss current recommendations regarding patient selection for biopsy and discuss future directions regarding prebiopsy imaging. We offer a description of the MRI–TRUS fusion biopsy technique and a comparison of many of the currently available fusion software platforms. Articles pertaining to the title were obtained via PubMed index search with relevant keywords supplemented with personal collection of related publications. Prostate biopsy should be considered for patients with gross digital rectal exam (DRE) abnormality, patients with a prostate-specific antigen (PSA) greater than 4 ng/ml, and concomitant risk factors for prostate cancer or patients with lesions identified on multiparametric MRI (mpMRI) with Prostate Imaging Reporting and Data System 2 (PI-RADS2) score of 4 or 5. MRI–TRUS fusion biopsy has demonstrated advantages in cancer detection when compared with TRUS-guided biopsy. There are currently several fusion software platforms available with a variety of biopsy approaches. Future efforts should detail the role of prebiopsy imaging as a triage tool for prostate biopsy. Consensus should be sought regarding the preferred modality of fusion biopsy. Additional data describing each fusion software platform would enable a more rigorous comparison of platform sensitivities.

Sign in / Sign up

Export Citation Format

Share Document